Neuralgia medical therapy
|
Neuralgia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuralgia medical therapy On the Web |
|
American Roentgen Ray Society Images of Neuralgia medical therapy |
|
Risk calculators and risk factors for Neuralgia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Parth Vikram Singh, MBBS
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Medical Therapy
The goal of treatment is to reverse or control the cause of the nerve problem (if found), and provide pain relief. Treatment varies depending on the cause, location, and severity of the pain, and other factors. Even if the cause of the neuralgia is never found, the condition may improve on its own or disappear with time. Strict control of blood sugar may speed recovery in people with diabetes who develop neuralgia. Medications to control pain may include:
- Antidepressant medications (amitriptyline, nortriptyline, or duloxetine)
- Antiseizure medications (carbamazepine, gabapentin, lamotrigine, phenytoin, or pregabalin)
- Mild over-the-counter analgesics (aspirin, acetaminophen, or ibuprofen)
- Narcotic analgesics (codeine) for short-term relief of severe pain (however, these do not always work well)
- Topical creams containing capsaicin
Other treatments may include:
- Local injections of pain-relieving (anesthetic) drugs
- Nerve blocks
- Physical therapy (may be needed for some types of neuralgia, especially postherpetic neuralgia)
- Procedures (such as nerve ablation using radiofrequency, heat, balloon compression, or injection of chemicals) to reduce feeling in the nerve
Unfortunately, these procedures may not improve symptoms and can cause loss of feeling or abnormal sensations.
When other treatment methods fail, doctors may try motor cortex stimulation (MCS). An electrode is placed over part of the brain and is hooked to a pulse generator under the skin.
Non-pharmacologic Therapy
Electroanalgesia
Electroanalgesia is a nonpharmacologic pain-management approach that delivers electrical stimulation through cutaneous electrodes to modulate pain signaling. Contemporary forms of electroanalgesia are used primarily in patients with Chronic pain and Neuropathic pain, particularly when pharmacologic therapies are ineffective or poorly tolerated. [1]
Two commonly used forms of cutaneous electroanalgesia are transcutaneous electrical nerve stimulation (TENS) and scrambler therapy, which differ in mechanisms, clinical application, and duration of analgesic effect.
1. Transcutaneous Electrical Nerve Stimulation (TENS)
Mechanism of Action
TENS devices administer low-intensity electrical stimulation through adhesive electrodes placed on the skin over areas of pain. The analgesic effect was initially explained by the gate-control theory, whereby stimulation of large-diameter Aβ fibers inhibits transmission of nociceptive signals from Aδ and C fibers in the dorsal horn. Subsequent studies suggest additional mechanisms, including reduced dorsal-horn neuron sensitization, inhibition of excitatory neurotransmitters, facilitation of endogenous opioid release, and activation of peripheral adrenergic receptors.
Clinical Evidence
Randomized trials and meta-analyses show modest to moderate reductions in pain intensity during or immediately after TENS, particularly in neuropathic pain. However, evidence quality is limited by heterogeneity in device parameters, study populations, and outcome measures. The analgesic effect typically dissipates within minutes to hours after stimulation is discontinued.
Safety and Limitations
TENS is generally well tolerated, with minor skin irritation being the most common adverse effect. It is contraindicated in patients with pacemakers, epilepsy, or skin injury at electrode sites. Despite widespread availability and safety, high-quality evidence supporting sustained benefit in chronic pain remains limited.
2. Scrambler Therapy
Mechanism of Action
Scrambler therapy is a distinct form of electroanalgesia that delivers continuously varying electrical waveforms designed to replace painful signals with non-noxious information. The therapy targets cutaneous C-fiber receptors and delivers non-painful electrical signals along pain pathways, which may interrupt persistent nociceptive input and thereby reduce central nervous system sensitization. Neuroimaging and biomarker studies suggest possible effects on cerebral pain networks and neuroinflammatory mediators.
Clinical Evidence
Randomized trials and meta-analyses demonstrate substantial reductions in pain intensity in patients with chronic neuropathic pain, cancer-related pain, and opioid-resistant pain, with standardized mean differences indicating a large effect size. In contrast to TENS, analgesic effects of scrambler therapy may persist for weeks, months, or longer after a treatment course.
Safety and Practical Considerations
Scrambler therapy is administered in supervised clinical settings. Reported adverse effects are rare and generally mild, including contact dermatitis or minor bruising. The therapy is contraindicated in patients with implanted cardiac devices or uncontrolled epilepsy.
Role of Electroanalgesia in Chronic Pain Management
Electroanalgesia may be considered as part of a multimodal, nonpharmacologic strategy for chronic pain, particularly in patients with neuropathic or refractory pain and in those seeking to reduce opioid or other analgesic medication use. Current evidence supports short-term analgesic benefit with TENS and more durable pain relief with scrambler therapy, though larger sham-controlled trials are needed to better define patient selection and long-term outcomes.
Limitations of Current Evidence
The primary limitations of electroanalgesia research include small sample sizes, difficulty in blinding interventions, heterogeneity of stimulation protocols, and incomplete understanding of mechanisms. Further randomized, sham-controlled trials are required to clarify efficacy, durability of response, and predictors of treatment success.
| Feature | TENS | Scrambler Therapy |
|---|---|---|
| Theoretical model | Gate-control theory: stimulation of large-diameter afferent fibers inhibits nociceptive transmission | Artificial neurons replace chronic pain signals with nonpain waveforms, potentially resetting central sensitization |
| Primary neural target | Aβ fibers in peripheral nerves of affected dermatomes | Surface receptors of C fibers in affected dermatomes |
| Signal characteristics | Linear pulse, typically rectangular waveform; 30–150 mA; ~80 Hz | Continuously varying signals resembling action potentials; maximum ~5.5 mA; 43–52 Hz |
| Mechanistic emphasis | Modulation of spinal nociceptive transmission via inhibitory interneurons | Replacement of painful information with non-noxious sensory input |
| Main clinical indications | Acute musculoskeletal pain; physical therapy adjunct | Chronic neuropathic pain and cancer-related pain, especially opioid-resistant pain |
| Duration of analgesic effect | Benefit generally stops when stimulation stops; may persist for hours | Analgesic effects may persist for weeks, months, or years after treatment |
| Operator control | Patient-adjustable magnitude and frequency | Output is fixed by proprietary algorithm; not adjustable by operator |
| Availability | Over-the-counter; no medical supervision required | Restricted to trained clinicians under physician supervision |
| Device cost | Approximately $20–$300 | Approximately $65,000 |
| Regulatory status | Widely available consumer devices | FDA-approved (2009) for supervised clinical use |
| Safety profile | Minor skin irritation or erythema; no serious adverse events reported | Rare mild adverse effects (e.g., contact dermatitis, ecchymosis); no serious adverse events reported |
| Contraindications | Pacemakers, epilepsy, skin injury at electrode site | Pacemakers, defibrillators, implanted neurostimulators, uncontrolled epilepsy |
References
- ↑ 1.0 1.1 Smith TJ, Wang EJ, Loprinzi CL (July 2023). "Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain". N Engl J Med. 389 (2): 158–164. doi:10.1056/NEJMra2110098. PMID 37437145 Check
|pmid=value (help). - ↑ Smith TJ, Wang EJ, Loprinzi CL (July 2023). "Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain". N Engl J Med. 389 (2): 158–164. doi:10.1056/NEJMra2110098. PMID 37437145 Check
|pmid=value (help).